Profiel
Jean-François Le Bigot is currently the Chief Executive Officer at Oncovita SAS and the Chairman at Ginko Invest.
He was previously the Director at Affluent Medical SA from 2020 to 2022.
Actieve functies van Jean-François Le Bigot
| Bedrijven | Functie | Begin |
|---|---|---|
Oncovita
 Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Algemeen Directeur | - |
Ginko Invest
 Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Voorzitter | - |
Eerdere bekende functies van Jean-François Le Bigot
| Bedrijven | Functie | Einde |
|---|---|---|
| AFFLUENT MEDICAL | Directeur/Bestuurslid | 19-01-2022 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AFFLUENT MEDICAL | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Ginko Invest
Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Finance |
Oncovita
Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Health Technology |
